title: Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia.
authors.forename: Hiroko
authors.initials: H
authors.lastname: Nishida
authors.forename: Natsuko
authors.initials: N
authors.lastname: Yoshimizu
authors.forename: Hironori
authors.initials: H
authors.lastname: Ueno
authors.forename: Ayumi
authors.initials: A
authors.lastname: Fujita
authors.forename: Takayasu
authors.initials: T
authors.lastname: Kato
authors.forename: Jae Wong
authors.initials: JW
authors.lastname: Park
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yano
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000208:Acute Disease; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000175:diagnosis*; D008297:Male; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D016044:Fusion Proteins, bcr-abl